Literature DB >> 19158847

Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors.

A A Rahim1, A M S Wong, S J Howe, S M K Buckley, A D Acosta-Saltos, K E Elston, N J Ward, N J Philpott, J D Cooper, P N Anderson, S N Waddington, A J Thrasher, G Raivich.   

Abstract

Non-integrating lentiviral vectors show considerable promise for gene therapy applications as they persist as long-term episomes in non-dividing cells and diminish risks of insertional mutagenesis. In this study, non-integrating lentiviral vectors were evaluated for their use in the adult and fetal central nervous system of rodents. Vectors differentially pseudotyped with vesicular stomatitis virus, rabies and baculoviral envelope proteins allowed targeting of varied cell populations. Efficient gene delivery to discrete areas of the brain and spinal cord was observed following stereotactic administration. Furthermore, after direct in utero administration (E14), sustained and strong expression was observed 4 months into adulthood. Quantification of transduction and viral copy number was comparable when using non-integrating lentivirus and conventional integrating vector. These data support the use of non-integrating lentiviral vectors as an effective alternative to their integrating counterparts in gene therapy applications, and highlight their potential for treatment of inherited and acquired neurological disorders.

Entities:  

Mesh:

Year:  2009        PMID: 19158847     DOI: 10.1038/gt.2008.186

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  46 in total

Review 1.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 2.  Transfection techniques for neuronal cells.

Authors:  Daniela Karra; Ralf Dahm
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

3.  High transgene expression by lentiviral vectors causes maldevelopment of Purkinje cells in vivo.

Authors:  Yusuke Sawada; Go Kajiwara; Akira Iizuka; Kiyohiko Takayama; Anton N Shuvaev; Chiho Koyama; Hirokazu Hirai
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

Review 4.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

Review 5.  Integration-deficient lentiviral vectors: a slow coming of age.

Authors:  Klaus Wanisch; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2009-06-02       Impact factor: 11.454

Review 6.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

Review 7.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

8.  Transgene expression in the mouse cerebellar Purkinje cells with a minimal level of integration using long terminal repeat-modified lentiviral vectors.

Authors:  Kiyohiko Takayama; Takashi Torashima
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

Review 9.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

Review 10.  Genetic therapy for the nervous system.

Authors:  William J Bowers; Xandra O Breakefield; Miguel Sena-Esteves
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.